Blogs about Biotechnology, Pharmaceutical and Healthcare

16:24 EDT 30th March 2017 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 95,000+

Thursday 30th March 2017

Venture Firm’s Incubator Watershed Buys Biomedical Product Developer

San Antonio—Watershed Idea Foundry, a life science incubator operated by a San Antonio venture capital firm, has acquired a similar product development and commercialization business, Encinitas, CA-based Additive Innovations. Watershed, which offers startups services such as proof-of-concept testing and prototype manufacturing in exchange for equity, is keeping its name but making Additive...

FDA: Helping Small Businesses Get Big Results

By: Brenda Stodart, Pharm.D., and Renu Lal, Pharm. D. It is well known that small business is vital to the success of the American economy. Less known, though, is how instrumental it has been to the growth and innovation in … Continue reading →

In Minnesota, new health rankings show a north-south divide

Susan Perry Minnesota has a north-south health divide: Its healthiest counties tend to be in the southern part of the state and its least healthy ones in the northern part, according to the 2017 “County Health Rankings” released Wednesday by the Robert Wood Johnson Foundation and the University of Wisconsin Population Health Institute.Of...

Boston Scientific to Acquire Heart Device Maker Symetis for $435M

[Updated 3/30/17, 2:12 pm. See below.] Boston Scientific is acquiring Swiss company Symetis, the latest move made by the medical device giant to strengthen its portfolio of minimally invasive heart valve replacement products. Marlborough, MA-based Boston Scientific (NYSE: BSX) will pay $435 million in upfront cash to Symetis. With the deal in place, Symetis has […]

Republican Kansas Governor Rejects Medicaid Expansion And His Own Party

Republican Kansas Gov. Sam Brownback vetoed legislation approved by state lawmakers from his own party to expand Medicaid health coverage under the Affordable Care Act.

Lilly Faces Tricky Opt-In Decision On Fruquintinib

AngioDynamics' (ANGO) CEO Jim Clemmer on F3Q 2017 Results - Earnings Call Transcript

France: Discover myDiabby

Today’s post is from Laurent Doucet, Diabetes Business Unit Director, Lilly France  With 10,000 remote consultations carried out for nearly 1,000 pregnant women enrolled every month in France, how did myDiabby become the largest telemedicine programme in the country? The platform has the potential to revolutionise the management of this chronic disease that affects an increasing number of peopl...

Progenics Pharmaceuticals (PGNX) Presents On Targeting and Treating Cancer - Slideshow

Fresenius Medical Care AG & Co. (FMS) Presents At Bankhaus Lampe Deutschlandkonferenz - Slideshow

Basilea Pharmaceutica AG (BPMUF) Presents At 18th Kepler Cheuvreux Swiss Seminar - Slideshow

Advair Lives Another Day

MannKind Corp.: Bleeding Out And On Its Deathbed

Roche Holding (RHHBF) Presents At 18th Kepler Cheuvreux Swiss Seminar - Slideshow

Vitamin D & cancer: How can two news releases about the same study be polar opposites?

I’ll admit this is predictable, but I can’t resist: It’s a tale of two news releases. Released on the same day, about the same study, but with very different headlines. But first, the study: a randomized, placebo-controlled study run over four years by Creighton University, in collaboration with the University of California San Diego, with the objective […]

If Trump Is Really Softening On Mexico, NAFTA, I'm Savoring The Moment

President Trump might just be back-pedaling and only planning minor revisions to the North America Free Trade Agreement. That's good, because the data suggests Mexico -- the most frequent subject of his vitriol pre- and post-campaign -- is actually a pretty good trade partner, and getting better.

Rosetta Genomics's (ROSG) CEO Ken Berlin on Q4 2016 Results - Earnings Call Transcript

High Medicare Part D Drug Prices Are Inflating Pharmaceutical Industry Profits

3 Possible Biotech Takeout Targets In The Second Quarter

Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q4 2016 Results - Earnings Call Transcript

Merck Outsources the Development of its Nanobody for Psoriasis

Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase II through Phase III. As part of several partnerships between Merck and the unbeaten nanobody biotech Ablynx, Merck recently cleared Phase ... This awesome article Merck Outsources the Development of its Nanobody for Psoriasis appeared first on Be kind and...

The need to marry socioeconomics, public health, and medical care is long overdue

I was recently invited to speak at a conference in what is likely the nicest hotel I have ever set foot in. Partially hidden by an array of palm trees and adjacent to a golf course, I could easily see why the conference rate was $350 per night. Before making my way to the conference […]

NeuroDerm's (NDRM) CEO Oded Lieberman on Q4 2016 Results - Earnings Call Transcript

Third Rock’s Tango Aims For Drugs That Turn Cancer Against Itself

As the understanding of cancer advances, scientists are discovering built-in features of the disease’s own biology that can be tapped to halt its growth. Biotech startup Tango Therapeutics believes it can build on this concept to develop new cancer drugs, and it is now unveiling its approach, backed by $55 million in financing. The Series […]

Next Stop on Father’s Duchenne Quest: Wall Street? Solid Raises $50M

It wasn’t too long ago that Ilan Ganot was a J.P. Morgan banker. Then his son, Eytani, was diagnosed with Duchenne muscular dystrophy, and he ended up the head of a startup trying to find an array of treatments for the progressive, deadly genetic disease. Now it appears that journey might return Ganot to a […]

Quick Search